Skip to main content
. 2012 Jan;180(1):410–418. doi: 10.1016/j.ajpath.2011.09.016

Figure 3.

Figure 3

A: Microangiography at the end of the treatment period in all groups. Images were assembled to obtain a complete view of the hind limb; each picture is representative of n = 4. Red arrows indicate femoral artery ligation. B: Example of immunostaining with specific antibodies for CD31 (green staining), α-actin (red staining), and nucleus (blue staining) in ischemic hind limbs. White arrows indicate α-actin in top left panel, CD31 in top right panel, and combination in lower right panel. C: Quantitative data (score in percent) showing vessel density in hind limb using Multi Gauge - FUJIFILM by selecting the same area of measurements in all groups, n = 4. D: Quantitative data of CD31 staining in hind limb in all groups. E: cGMP levels in ischemic hind limb in all groups. C–E: *P < 0.05 for diabetic versus control, ‡P < 0.05 indicating a significant difference between diabetic versus diabetic treated with AG1478 (AG), and †P < 0.05 for diabetic versus diabetic treated with U0126 (U0).